Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 3 (March)

1. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
   Glia, 53(6): 593-600. [Abstract] [Full-text]
2. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
   Phys Med Biol, 51(6): 1377-91. [Abstract] [Full-text]
3. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
   Immunol Lett, 104(1): 146-55. [Abstract] [Full-text]
4. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
   Oncol Nurs Forum, 33(2): 265-72. [Abstract] [Full-text]
5. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
   Am J Health Syst Pharm, 63(6): 527-33. [Abstract] [Full-text]
6. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
   Clin Cancer Res, 12(5): 1470-8. [Abstract] [Full-text]
7. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
   Appl Immunohistochem Mol Morphol, 14(1): 103-8. [Abstract] [Full-text]
8. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.
   Cancer Treat Rev, 32(2): 106-18. [Abstract] [Full-text]
9. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.
   Cancer Lett, 234(2): 176-83. [Abstract] [Full-text]
10. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells.
    Anticancer Drugs, 17(4): 455-62. [Abstract] [Full-text]
11. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Clin Cancer Res, 12(6): 1715-20. [Abstract] [Full-text]
12. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
    Ann Oncol, 17(4): 630-6. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.